ScreenerHero

NXTCL NextCell Pharma AB

STO · SE · Healthcare · Biotechnology · nextcellpharma.com
1.006SEK-1.37%Mkt Cap: 12.33M $P/E: —

NextCell Pharma AB, a biopharmaceutical company, engages in the research, development, and manufacture of stromal cell therapies in Sweden. Its lead drug candidate is ProTrans, a cell therapy with mesenchymal stromal cel…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap12.33M USD
Enterprise Value11.16M USD
Revenue (TTM)1.03M USD
Gross Profit156.00K USD
Net Income (TTM)-3.76M USD
Revenue/Share0.09 SEK
Last Price1.006 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees—
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0009723125
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-2.91
EV/Revenue10.83
P/S12.78
P/B2.93
EPS (TTM)-0.43
EPS (Forward)—
52W Range
0.630033% of range1.784
52W High1.784 SEK
52W Low0.6300 SEK
Profitability
Gross Margin16.38%
Oper. Margin-386.44%
EBITDA Margin0.00%
Profit Margin-395.19%
ROE-77.77%
ROA-61.57%
Growth
Revenue Growth102.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.61M USD
CapEx (TTM)7.93K USD
FCF Margin—
FCF Yield—
Net Debt-2.02M USD
Net Debt/EBITDA0.53
Balance Sheet
Debt/Equity—
Current Ratio3.71
Quick Ratio3.68
Book Value/Sh0.37 SEK
Cash/Share0.17 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 SEK
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)2.900 SEK
Upside (mean)+188.3%
Target Range2.900 SEK – 2.900 SEK
# Analysts1
Ownership
Shares Out.126.39M
Float101.65M
Insiders15.32%
Institutions29.33%
Technical
SMA 501.072 (-6.2%)
SMA 2001.153 (-12.7%)
Beta0.68
S&P 52W Chg16.45%
Avg Vol (30d)364.84K
Avg Vol (10d)372.62K
Technical Indicators
RSI (14)45.0
MACD-0.0057
MACD Signal-0.0040
MACD Hist.-0.0016
BB Upper1.140 SEK
BB Middle1.066 SEK
BB Lower0.9925 SEK
BB Width13.79%
ATR (14)0.0760 SEK
Vol Ratio (20d)0.77x